GlassScriptPhysician profile
Matthew H Pham
NPI 1003917055
$8,928.27
in general payments reported to CMS, 2019-2025
31 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $658 · 2021: $1,374 · 2022: $629 · 2023: $1,552 · 2024: $2,026 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,148.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,445.68 | 2019-2025 | Aveir, Jot Dx, Gallant |
| Pfizer INC. | $306.31 | 2023-2025 | |
| Glaxosmithkline, LLC. | $288.82 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $253.61 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $224.80 | 2023-2025 | Veozah |
| Cvrx, INC. | $194.38 | 2023 | Barostim Neo System |
| Stryker Corporation | $152.98 | 2024 | |
| Radius Health, INC. | $124.97 | 2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.31 | 2023-2025 | Jardiance |
| Amgen INC. | $104.41 | 2023-2024 | Repatha, Otezla |
| Lilly USA, LLC | $99.03 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Lundbeck LLC | $76.93 | 2024-2025 | Rexulti |
| Abbvie INC. | $73.54 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $51.18 | 2024-2025 | Gemtesa |
| Shield Therapeutics INC | $39.90 | 2023-2024 | Accrufer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39.44 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $38.74 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $36.26 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $34.11 | 2024 | Xarelto |
| Medtronic, INC. | $32.58 | 2025 | Symplicity G3 |
| Dexcom, INC. | $28.23 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $23.34 | 2025 | Capvaxive, Gardasil 9 |
| Boston Scientific Corporation | $18.29 | 2025 | General - Pain Management |
| Exact Sciences Corporation | $18.00 | 2024 | Cologuard Collection Kit |
| Tolmar, INC. | $16.75 | 2025 | Jatenzo |
| Axsome Therapeutics, INC. | $15.90 | 2025 | Symbravo |
| Depuy Synthes Sales INC. | $15.67 | 2024 | Trumatch |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.21 | 2025 | Caplyta |
| Halozyme INC | $14.11 | 2023 | |
| Inogen, INC. | $13.75 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.04 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.